InspireMD (NYSE:NSPR) Now Covered by StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR – Get Free Report) in a report issued on Wednesday. The brokerage set a “sell” rating on the stock.

A number of other equities research analysts have also recently weighed in on NSPR. Alliance Global Partners reduced their price target on shares of InspireMD from $5.15 to $4.75 in a research report on Wednesday, May 17th. Piper Sandler started coverage on shares of InspireMD in a report on Monday, June 12th. They issued an “overweight” rating for the company.

Get InspireMD alerts:

InspireMD Stock Performance

Shares of NYSE NSPR opened at $3.12 on Wednesday. The stock’s 50-day simple moving average is $2.08 and its 200-day simple moving average is $1.48. The firm has a market capitalization of $26.08 million, a PE ratio of -1.36 and a beta of 0.94. InspireMD has a fifty-two week low of $0.81 and a fifty-two week high of $3.74.

InspireMD (NYSE:NSPR – Get Free Report) last released its quarterly earnings data on Monday, May 15th. The company reported ($0.53) earnings per share for the quarter. The company had revenue of $1.24 million for the quarter. InspireMD had a negative return on equity of 93.16% and a negative net margin of 349.45%. On average, sell-side analysts forecast that InspireMD will post -1.11 earnings per share for the current fiscal year.

Insider Buying and Selling at InspireMD

In other news, Director Paul Stuka acquired 175,000 shares of the business’s stock in a transaction on Friday, May 12th. The stock was bought at an average price of $1.63 per share, for a total transaction of $285,250.00. Following the transaction, the director now owns 248,534 shares in the company, valued at $405,110.42. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 3.80% of the company’s stock.

InspireMD Company Profile

(Get Free Report)

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Delivery System, a mesh-covered self-expanding carotid stent; SwitchGuard, a non-invasive transcarotid artery revascularization device; and NGuard EPS for treating acute stroke with tandem lesions.

Read More

• Five stocks we like better than InspireMD
• Green Hydrogen Stocks Getting Ready to Deliver Big Gains
• Charles Schwab Gets The Rebound, Time to Buy?
• Is Ebix Inc a Phygital E-Commerce Contender or Pretender?
• 3 Mid-Cap Stocks with Expectations for High-Earnings Growth
• Can Lockheed Martin Fly To A New High In 2023?

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.